We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+24.41%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.16B
AUM Growth
+$121M
Cap. Flow
-$26.6M
Cap. Flow %
-1.23%
Top 10 Hldgs %
45.97%
Holding
84
New
9
Increased
5
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$53.6M
2
LEGN icon
Legend Biotech
LEGN
+$39.2M
3
AKRO
Akero Therapeutics
AKRO
+$38.7M
4
IMGN
Immunogen Inc
IMGN
+$35M
5
ARGX icon
argenx
ARGX
+$29.5M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$204M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$40.5M
3
BLU
BELLUS Health Inc.
BLU
+$23M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$22.6M
5
MORF
Morphic Holding, Inc. Common Stock
MORF
+$7.53M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
26
Axsome Therapeutics
AXSM
$11.2B
$28.7M 1.33%
400,000
– –
ITOS
27
DELISTED
iTeos Therapeutics
ITOS
$28.5M 1.32%
2,154,058
– –
VTYX
28
DELISTED
Ventyx Biosciences
VTYX
$27.9M 1.29%
850,000
– –
ANAB icon
29
AnaptysBio
ANAB
$1.58B
$26.4M 1.23%
1,300,000
– –
IOVA icon
30
Iovance Biotherapeutics
IOVA
$1.82B
$26.1M 1.21%
3,705,133
– –
TNGX icon
31
Tango Therapeutics
TNGX
$4.43B
$23.6M 1.1%
7,123,642
– –
MDGL icon
32
Madrigal Pharmaceuticals
MDGL
$10.8B
$23.1M 1.07%
+100,000
New +$27.1M
XENE icon
33
Xenon Pharmaceuticals
XENE
$6.06B
$23.1M 1.07%
600,000
– –
RLAY icon
34
Relay Therapeutics
RLAY
$4.1B
$22.8M 1.06%
1,819,132
-350,000
-16% -$4.35M
PNT
35
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$22.6M 1.05%
2,500,000
– –
EXEL icon
36
Exelixis
EXEL
$13.3B
$22M 1.02%
1,150,000
– –
PRTA icon
37
Prothena Corp
PRTA
$425M
$20.5M 0.95%
300,000
– –
PMVP icon
38
PMV Pharmaceuticals
PMVP
$59.2M
$19.8M 0.92%
3,163,795
– –
KALV
39
DELISTED
KalVista Pharmaceuticals
KALV
$14.8M 0.69%
1,650,000
– –
ELVN icon
40
Enliven Therapeutics
ELVN
$3.92B
$14.5M 0.67%
710,644
– –
DAWN
41
DELISTED
Day One Biopharmaceuticals
DAWN
$14.2M 0.66%
1,189,943
– –
ORIC icon
42
Oric Pharmaceuticals
ORIC
$1.15B
$13.4M 0.62%
1,732,571
+678,571
+64% +$3.85M
ZNTL icon
43
Zentalis Pharmaceuticals
ZNTL
$337M
$12.7M 0.59%
+450,000
New +$10.8M
RNAM
44
DELISTED
Avidity Biosciences
RNAM
$12.4M 0.58%
1,121,327
– –
NRIX icon
45
Nurix Therapeutics
NRIX
$2.41B
$12.2M 0.57%
1,224,892
– –
CGEM icon
46
Cullinan Oncology
CGEM
$1.01B
$11.6M 0.54%
1,074,082
– –
PRLD icon
47
Prelude Therapeutics
PRLD
$366M
$11.2M 0.52%
2,495,018
+1,795,971
+257% +$10.7M
BDTX icon
48
Black Diamond Therapeutics
BDTX
$96.8M
$10.2M 0.47%
2,014,858
– –
GERN icon
49
Geron
GERN
$828M
$9.63M 0.45%
+3,000,000
New +$8.54M
ASND icon
50
Ascendis Pharma A/S
ASND
$16B
$8.48M 0.39%
95,000
– –
1
2
3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Boxer Capital held 84 positions worth $2.16B, up 5.9% from $2.04B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Boxer Capital's Q2 2023 filing shows 9 new, 5 increased, 5 reduced and 5 closed positions. Its largest new stake was Karuna Therapeutics, Inc. Common Stock: 250,000 shares worth $54.2M. The largest sale was Prometheus Biosciences, Inc. Common Stock, an estimated $204M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q2 2023 buy was Karuna Therapeutics, Inc. Common Stock: 250,000 shares worth $54.2M.
  • Boxer Capital added most to Akero Therapeutics in Q2 2023, an estimated $38.7M increase.
  • Boxer Capital's biggest Q2 2023 reduction was Sarepta Therapeutics, cutting an estimated $22.6M.
  • Boxer Capital fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $204M.
  • Boxer Capital's ten largest holdings make up 46% of its $2.16B portfolio in Q2 2023.
  • Boxer Capital opened 9 new positions and closed 5 in Q2 2023.
  • Boxer Capital's portfolio value rose 5.9% quarter-over-quarter to $2.16B.

Based on Boxer Capital's 13F filing for Q2 2023, filed 14 Aug 2023.